Last €63.49 EUR
Change Today +0.288 / 0.46%
Volume 3.0K
LLY On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
EN Paris
As of 12:25 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lilly Corporate Center

Indianapolis, IN 46285

United States

Phone: 317-276-2000


pulmonary arterial hypertension. Animal Health Products The company’s products for food animals include Rumensin, a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Posilac, a protein supplement to improve milk productivity in dairy cows; Paylean and Optaflexx, leanness and performance enhancers for swine and cattle, respectively; Tylan, an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil, Pulmotil, and Pulmotil AC antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively; Coban, Monteban, and Maxiban anticoccidial agents for use in poultry; and Surmax (sold as Maxus in some countries), a performance enhancer for swine and poultry. The company’s products for companion animals include Trifexis, a monthly chewable tablet for dogs that kills fleas, prevents flea infestations, prevents heartworm disease, and controls intestinal parasite infections; and Comfortis, a chewable tablet that kills fleas and prevents flea infestations on dogs. Marketing The company sells majority of its products worldwide. Human Pharmaceuticals—United States: In the U.S., the company distributes human pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies. In 2013, its wholesale distributors in the U.S. included AmerisourceBergen Corporation; McKesson Corporation; and Cardinal Health, Inc. The company maintains special business groups to service wholesalers, pharmacy benefit managers, managed-care organizations (MCOs), government and long-term care institutions, hospitals, and certain retail pharmacies. Human Pharmaceuticals—Outside the United States: Outside the U.S, the company promotes its human pharmaceutical products primarily through sales representatives. In various countries, it maintains its own sales organizations, and in some smaller countries, the company markets its products through independent distributors. Human Pharmaceutical Marketing Collaborations The company co-markets Cymbalta in Japan with Shionogi & Co. Ltd. Evista is marketed in major European markets by Daiichi Sankyo Europe GmbH, a subsidiary of Daiichi Sankyo Co., Ltd. (Daiichi Sankyo). Erbitux is marketed in the U.S. and Canada by Bristol-Myers Squibb. The company has the option to co-promote Erbitux in the U.S. and Canada. Outside the U.S. and Canada, Erbitux is commercialized by Merck KGaA. Effient is co-promoted with the company by Daiichi Sankyo or affiliated companies in the U.S., major European markets, Brazil, Mexico, and certain other countries. The company retains sole marketing rights in Canada, Australia, Russia, and certain other countries. Daiichi Sankyo retains sole marketing rights in Japan and certain other countries. Trajenta and Jentadueto are being jointly developed and commercialized with the company by Boehringer Ingelheim pursuant to a collaboration agreement under which both parties contributed certain diabetes treatments in mid- and late-stage development to be jointly developed and commercialized by the parties. Animal Health Products The company’s Elanco animal health business unit employs field salespeople throughout the U.S. and has a sales force outside the U.S. Elanco sells its products primarily to wholesale distributors. Elanco promotes its products primarily to producers and veterinarians for food animal products and to veterinarians for companion animal products. Elanco also advertises certain companion animal products directly to pet owners. Strategy The company’s strategy is to create value for all its stakeholders by accelerating the flow of innovative new medicines that provide improved outcomes for individual patients. Its Elanco animal health innovation strategy is focused on identifying and developing promising technologies and potential products from internal and external sources to meet unmet veterinary needs. Intellectual Property Portfolio The U.S. patent protection or data protection for the company’s launched patent-protected marketed products includes Alimta is protected by a compound


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €63.49 EUR +0.288

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.10 USD +0.42
AbbVie Inc $63.00 USD -0.0952
AstraZeneca PLC 4,744 GBp +18.50
Novo Nordisk A/S kr298.40 DKK +1.00
Teva Pharmaceutical Industries Ltd $58.31 USD -0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation LLY Industry Range
Price/Earnings 28.7x
Price/Sales 3.8x
Price/Book 4.3x
Price/Cash Flow 29.7x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at